TNXP: Tonix Pharmaceuticals Company Short-Term Debt
Tonix Pharmaceuticals (TNXP) actively collaborates with scientific centers to develop anti-infectives, analgesics, and vaccines for CNS therapy. The business relies on an autonomous production cycle that remains independent of global disruptions, providing the asset with defensive qualities. The market trend for this diversified pharmaceutical company's share price on GURU.Markets is recorded at 0.00.
Analytical breakdowns and data insights for company Tonix Pharmaceuticals Holding (TNXP)
This indicator tracks the total liabilities of Tonix Pharmaceuticals (TNXP) with a maturity of up to one year. The metric's trend reflects current liquidity and the company's ability to cover operating expenses. By analyzing short-term borrowed resources, an investor assesses the risk of a cash shortfall. For a non-cyclical pharmaceutical business, such debt transparency is critical during transitions between research phases. The stability of this figure confirms the resilience of drug development against macroeconomic fluctuations.